Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s share price traded up 6.7% during mid-day trading on Wednesday . The stock traded as high as $1.60 and last traded at $1.60. 200 shares were traded during trading, a decline of 83% from the average session volume of 1,150 shares. The stock had previously closed at $1.50.
Silence Therapeutics Stock Performance
The business’s 50 day simple moving average is $1.72 and its 200 day simple moving average is $1.65.
Silence Therapeutics Company Profile
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
